CN111743855A - 一种类风湿性关节炎治疗凝胶制剂的合成方法 - Google Patents
一种类风湿性关节炎治疗凝胶制剂的合成方法 Download PDFInfo
- Publication number
- CN111743855A CN111743855A CN202010220221.5A CN202010220221A CN111743855A CN 111743855 A CN111743855 A CN 111743855A CN 202010220221 A CN202010220221 A CN 202010220221A CN 111743855 A CN111743855 A CN 111743855A
- Authority
- CN
- China
- Prior art keywords
- plga
- peg
- icg
- gel
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 14
- 206010039073 rheumatoid arthritis Diseases 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 230000002194 synthesizing effect Effects 0.000 title claims abstract description 9
- 229960004657 indocyanine green Drugs 0.000 claims abstract description 39
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 claims abstract description 32
- 229920000436 Poly(lactide-co-glycolide)-block-poly(ethylene glycol)-block-poly(lactide-co-glycolide) Polymers 0.000 claims abstract description 25
- 230000001506 immunosuppresive effect Effects 0.000 claims abstract description 14
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 13
- 239000000243 solution Substances 0.000 claims abstract description 13
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 6
- 239000000463 material Substances 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 238000005303 weighing Methods 0.000 claims description 7
- 239000012460 protein solution Substances 0.000 claims description 6
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 241000700605 Viruses Species 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- 238000010189 synthetic method Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 238000006243 chemical reaction Methods 0.000 abstract description 6
- 238000001727 in vivo Methods 0.000 abstract description 5
- 238000002156 mixing Methods 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 4
- 210000000987 immune system Anatomy 0.000 abstract description 4
- 210000005067 joint tissue Anatomy 0.000 abstract description 3
- 238000002347 injection Methods 0.000 abstract description 2
- 239000007924 injection Substances 0.000 abstract description 2
- 239000007788 liquid Substances 0.000 abstract description 2
- 230000014759 maintenance of location Effects 0.000 abstract description 2
- 231100000252 nontoxic Toxicity 0.000 abstract description 2
- 230000003000 nontoxic effect Effects 0.000 abstract description 2
- 230000002062 proliferating effect Effects 0.000 abstract description 2
- 210000002437 synoviocyte Anatomy 0.000 abstract description 2
- 230000036737 immune function Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 230000028993 immune response Effects 0.000 description 3
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 210000005222 synovial tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 101710188313 Protein U Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000010235 enterohepatic circulation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229920001002 functional polymer Polymers 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002165 photosensitisation Effects 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
- A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0073—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form semi-solid, gel, hydrogel, ointment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公布一种类风湿性关节炎治疗凝胶制剂的合成方法。主要步骤包括:1)PLGA‑PEG‑PLGA凝胶溶液的制备；2)混合法制备HIV‑Vpu蛋白免疫抑制凝胶。HIV‑Vpu蛋白可抑制机体免疫功能，抑制类风湿性关节炎的免疫过激反应，防止免疫系统攻击自身正常关节组织。吲哚菁绿(ICG)的荧光效应使凝胶治疗的过程可视化，其产生的光热效应也可清除增生的滑膜细胞。PLGA‑PEG‑PLGA无毒，生物相容性好，在常温下呈液态，35度左右相变为凝胶，可以很好地用于体内注射，延长药物在体内的滞留，从而提高治疗效果。
Description
技术领域
本发明涉及凝胶制剂的合成技术领域,具体涉及一种通过PLGA-PEG-PLGA包裹HIV病毒Vpu蛋白和吲哚菁绿(ICG)的策略,合成病毒蛋白免疫抑制凝胶制剂的方法。
背景技术
自身免疫性疾病是指对自身抗原的免疫耐受性丧失、组织自身抗原抗体的产生和自身免疫现象的发生。如果这些反应引起组织损伤并引起病理变化或临床症状，则称为自身免疫性疾病。类风湿关节炎的自身免疫理论已被大多数学者广泛接受。类风湿性关节炎常自然发病，反复发作，慢性迁延，终身不愈。患者的滑膜组织能合成大量的免疫球蛋白(包括类风湿因子)。类风湿性关节炎患者关节滑膜组织中有大量淋巴细胞和浆细胞聚集，反映了局部存在着活跃的免疫反应。关节部(包括滑液)有免疫球蛋白与补体形成的复合物，且关节液内补体浓度的降低程度与免疫复合物的活性一致。而HIV病毒产生的多种蛋白质在抑制免疫反应方面可发挥作用。其中辅助蛋白U(Vpu)可抑制一种叫做NF-kB的转录因子的激活，减少了在免疫反应中起关键作用的细胞因子的产生。
ICG化学名为吲哚菁绿，是一种感光染料，是美国食品药品监督管理局(FDA)惟一批准的体内应用染料。它注入血液后会迅速与清蛋白及α1-脂蛋白结合(98％)，随血液经过肝脏时，90％以上被肝细胞摄取，再以原形由胆道排泄，不参与体内化学反应，无肠肝循环，无淋巴逆流，不从肾脏等肝外脏器排泄，无辐射，无毒副作用。
PLGA-PEG-PLGA是一种三嵌段聚合物。其中PLGA由两种单体——乳酸和羟基乙酸随机聚合而成，是一种可降解的功能高分子有机化合物，其降解产物是乳酸和羟基乙酸，同时也是人代谢途径的副产物，所当它应用在医药和生物材料中时不会有毒副作用，具有良好的生物相容性、无毒、良好的成囊和成膜的性能。PEG具有良好的水溶性，生物相容性好，并赋予了聚合物温敏相变的性质。
发明内容
本发明为克服现有技术的不足，提供一种通过PLGA-PEG-PLGA包裹HIV病毒Vpu蛋白和吲哚菁绿(ICG)的策略,合成免疫抑制凝胶制剂的方法。利用Vpu蛋白抑制机体的特异性细胞免疫和体液免疫反应，抑制类风湿性关节炎的免疫过激反应，防止免疫系统攻击自身正常关节组织，以达到治疗类风湿性关节炎的目的。
本发明的技术方案是一种免疫抑制凝胶制剂的合成方法，通过PLGA-PEG-PLGA包裹HIV病毒Vpu蛋白和吲哚菁绿(ICG)的策略,具体步骤如下：
1)称取PLGA-PEG-PLGA材料，加入水中溶解，得到浓度为0.2-0.4mg/ml的PLGA溶液；
2)称取ICG材料，加入水中溶解，得到浓度为5-8mg/ml的ICG溶液；
3)各取适量混合成病毒免疫凝胶。
所述步骤3)具体如下：
(1)在室温下将盛有1ml的PLGA-PEG-PLGA溶液的单口瓶置于旋转搅拌器上，搅拌速度设定为500r/min；
(2)边搅拌边逐滴加入8uL的ICG水溶液和20uL Vpu蛋白溶液，继续搅拌直至完全混匀，最终得到HIV-Vpu蛋白@ICG免疫抑制凝胶。
本发明的优势在于：
1)Vpu蛋白可以抑制细胞免疫,抑制类风湿性关节炎的免疫过激反应，防止免疫系统攻击自身正常关节组织，以达到治疗类风湿性关节炎的目的。
2)吲哚菁绿(ICG)的荧光效应使治疗的过程可视化，其产生的光热效应也可清除清除增生的滑膜细胞。
3)PLGA-PEG-PLGA无毒，生物相容性好，在常温下呈液态，35度左右相变为凝胶，可以很好地用于体内注射，延长药物在体内的滞留，从而提高效果。
附图说明
图1：免疫抑制凝胶相变示意图。
具体实施方式
以下结合附图和具体实施例来对本发明作进一步的说明。
实施例1：
1)准确称取0.25mg的PLGA-PEG-PLGA材料，加入1mL水溶解，得到浓度为0.25mg/ml的PLGA-PEG-PLGA水溶液。
2)准确称取5mg的ICG材料，加入1mL水溶解，得到浓度为5mg/ml的ICG水溶液。
3)混合法合成HIV-Vpu蛋白@ICG免疫抑制凝胶的方法如下：
(1)在室温下将盛有1ml的PLGA-PEG-PLGA溶液的单口瓶置于旋转搅拌器上，搅拌速度设定为500r/min；
(2)边搅拌边逐滴加入8uL的ICG水溶液和20uL Vpu蛋白溶液，继续搅拌直至完全混匀，最终得到HIV-Vpu蛋白@ICG免疫抑制凝胶。
实施例2：
1)准确称取0.2mg的PLGA-PEG-PLGA材料，加入1mL水溶解，得到浓度为0.2mg/ml的PLGA-PEG-PLGA溶液。
2)准确称取8mg的ICG材料，加入1mL水溶解，得到浓度为8mg/ml的ICG水溶液。
3)混合法合成HIV-Vpu蛋白@ICG免疫抑制凝胶的方法如下：
(1)在室温下将盛有1ml的PLGA-PEG-PLGA溶液的单口瓶置于旋转搅拌器上，搅拌速度设定为500r/min；
(2)边搅拌边逐滴加入6uL的ICG水溶液和20uL Vpu蛋白溶液，继续搅拌直至完全混匀，最终得到HIV-Vpu蛋白@ICG免疫抑制凝胶。
实施例3：
1)准确称取0.4mg的PLGA-PEG-PLGA材料，加入1mL水溶解，得到浓度为0.4mg/ml的PLGA-PEG-PLGA溶液。
2)准确称取6mg的ICG材料，加入1mL水溶解，得到浓度为6mg/ml的ICG水溶液。
3)混合法合成HIV-Vpu蛋白@ICG免疫抑制凝胶的方法如下：
(1)在室温下将盛有1ml的PLGA-PEG-PLGA溶液的单口瓶置于旋转搅拌器上，搅拌速度设定为500r/min；
(2)边搅拌边逐滴加入10uL的ICG水溶液和20uL Vpu蛋白溶液，继续搅拌直至完全混匀，最终得到HIV-Vpu蛋白@ICG免疫抑制凝胶。
Claims (2)
1.一种类风湿性关节炎治疗凝胶制剂的合成方法，其特征是，通过PLGA-PEG-PLGA包裹HIV病毒Vpu蛋白和吲哚菁绿(ICG)的策略,具体步骤如下：
1)称取PLGA-PEG-PLGA材料，加入水中溶解，得到浓度为0.2-0.4mg/ml的PLGA-PEG-PLGA溶液；
2)称取ICG材料，加入水中溶解，得到浓度为5-8mg/ml的ICG溶液；
3)取6-10uL的ICG水溶液和20uLHIV病毒Vpu蛋白溶液加入1mlPLGA-PEG-PLGA水溶液中混合成免疫抑制凝胶。
2.根据权利要求1所述的类风湿性关节炎治疗凝胶制剂的合成方法，其特征是，所述步骤3)具体如下：
(1)在室温下将盛有1ml的PLGA-PEG-PLGA溶液的单口瓶置于旋转搅拌器上，搅拌速度设定为500r/min；
(2)边搅拌边逐滴加入6-10uL的ICG水溶液和20uLHIV病毒Vpu蛋白溶液，继续搅拌直至完全混匀，最终得到HIV-Vpu蛋白免疫抑制凝胶。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010220221.5A CN111743855A (zh) | 2020-03-25 | 2020-03-25 | 一种类风湿性关节炎治疗凝胶制剂的合成方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010220221.5A CN111743855A (zh) | 2020-03-25 | 2020-03-25 | 一种类风湿性关节炎治疗凝胶制剂的合成方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111743855A true CN111743855A (zh) | 2020-10-09 |
Family
ID=72673241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010220221.5A Pending CN111743855A (zh) | 2020-03-25 | 2020-03-25 | 一种类风湿性关节炎治疗凝胶制剂的合成方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111743855A (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102370611A (zh) * | 2010-08-17 | 2012-03-14 | 东莞太力生物工程有限公司 | 一种包含exendin-4的温度敏感型水凝胶及其注射剂 |
| CN110522926A (zh) * | 2019-08-06 | 2019-12-03 | 天津大学 | 一种可视化纳米免疫制剂及其制备方法、应用 |
-
2020
- 2020-03-25 CN CN202010220221.5A patent/CN111743855A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102370611A (zh) * | 2010-08-17 | 2012-03-14 | 东莞太力生物工程有限公司 | 一种包含exendin-4的温度敏感型水凝胶及其注射剂 |
| CN110522926A (zh) * | 2019-08-06 | 2019-12-03 | 天津大学 | 一种可视化纳米免疫制剂及其制备方法、应用 |
Non-Patent Citations (1)
| Title |
|---|
| SIMON LANGER ET AL.: ""HIV-1 Vpu is a potent transcriptional suppressor of NF-kB-elicited antiviral immune responses"", 《ELIFE》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1234416C (zh) | 持续释放疏水药物的组合物及其制备方法 | |
| CN103007288B (zh) | 改进的贮库制剂 | |
| JP5175017B2 (ja) | 有効成分の経口吸収を改善するための粒子状担体 | |
| JPH09503495A (ja) | 高濃度アセトアミノフェン溶液含有ゼラチンカプセル | |
| JPH11130697A (ja) | 薬物放出速度が制御された医薬組成物 | |
| CN101732728B (zh) | 抗炎药物-多糖偶联物及其药物组合物的制备和应用 | |
| CN106693040A (zh) | 一种可载药聚乙烯醇洗脱微球的制备方法 | |
| CN105859990B (zh) | 侧链含硫辛酰基的聚合物、其制备方法及由其制备的聚合物囊泡及其应用 | |
| CN107837229A (zh) | 一种缓释阿霉素脂质体的温敏水凝胶制剂及制备方法 | |
| US7781400B2 (en) | Pharmaceutical compositions comprising dextran with a molecular weight of 1.0-100 KDA and processes for their preparation | |
| CN107722304A (zh) | 触变氧化纤维素溶液及其医疗应用 | |
| JPH0840880A (ja) | 軟ゼラチンカプセル剤中のケトプロフエン溶液に基づく医薬製剤およびその調製法 | |
| CN111743855A (zh) | 一种类风湿性关节炎治疗凝胶制剂的合成方法 | |
| JP6472730B2 (ja) | 徐放性製剤 | |
| CN110974962B (zh) | 肿瘤免疫凝胶制剂的合成方法 | |
| CN110302389B (zh) | 一种抗血管生成的水凝胶缓释制剂及其应用 | |
| CN113786393A (zh) | 一种利伐沙班微球及其制备方法与应用 | |
| CN1302807C (zh) | 载有胰岛素的生物降解高分子微球及其制备方法 | |
| CN101301264A (zh) | 一种双重缓释抗癌注射剂 | |
| CN111450046A (zh) | 一种新冠病毒免疫凝胶制剂的合成方法 | |
| CN111450047A (zh) | 一种mers病毒免疫凝胶制剂的合成方法 | |
| EA021663B1 (ru) | Композиция с замедленным высвобождением, способ ее получения и способ лечения рака | |
| CN101347410A (zh) | 一种含十八基二甲基-4-哌啶磷酸盐的抗癌缓释注射剂 | |
| CN101347409A (zh) | 含十八基二甲基-4-哌啶磷酸盐的缓释注射剂 | |
| KR100558070B1 (ko) | 가용성 덱시부프로펜의 연질캅셀제 조성물 및 그의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201009 |
|
| RJ01 | Rejection of invention patent application after publication |